Published: 22 August, 2019 | Volume 4 - Issue 2 | Pages: 103-109
Figure 1:
Plasma biomarker measurements across all ACC/AHA HF stages. Box-and whisker plots of plasma biomarker concentrations with box plot boundaries representing 25th and 75th percentile, horizontal line denoting the median, whisker extending to 1.5x interquartile range; Statistical significance determined by Bonferroni post-hoc analyses to compare concentrations across HF groups; *p<0.05, denoting significant differences in plasma biomarker concentrations in stage D HF compared to stages A, B, and C for NTproBNP, pMMP-9, and IL-6; ACC/AHA, American College of Cardiology/American Heart Association; NTproBNP, N-terminal pro-Brain Natriuretic Peptide; cTnI, high sensitivity Troponin I; ET-1, Endothelin-1; pMMP-9, plasma Matrix Metalloproteinase-9; TNFα, Tumor Necrosis Factor-alpha; IL-6, Interleukin-6.
Read Full Article HTML DOI: 10.29328/journal.jccm.1001049 Cite this Article Read Full Article PDF
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."